The Talent Architecture
Formation Bio pays its General Managers up to $388,500, Zero G Talent board's data shows, to run AI-driven drug programs that compress two-month recruitment campaigns into minutes. The company's live postings show roles across clinical development, technology, and business development: General Manager (Drug Asset Lead), Senior Director or Vice President of Product, Director of Product – Applied Data Science, Director of Data Science, Director of Business Development – Search & Evaluation, and Associate Director of Data Science focused on Real World Data.
This guide outlines who Formation Bio hires, what they earn, and how the selection process works, drawn from the company's job boards, third-party aggregators, leadership announcements, and candidate reports.
Clinical leadership comes from the upper ranks of traditional pharma. Louis Brenner, MD, joined as Chief Medical Officer in September 2025 after more than 20 years across biotech and large pharma. Daniel Neil, PhD, appointed Chief Technology Officer the same month, brings deep machine learning expertise, executive leadership, and biomedical industry experience. Business development operates as an investment function: Frank D'Amelio, former Pfizer CFO, serves as Co-Chair of the Investment Advisory Committee alongside Dashyant Dhanak, most recently EVP and CSO at Deciphera, and Mikael Dolsten, former Pfizer CSO.
Product and data science teams absorb the output of the AI systems the company builds internally. The "Muse" system, described in a CNBC interview, compressed a two-month patient recruitment campaign — PhDs and clinicians researching disease areas, segmenting populations, drafting IRB-approved protocols, brochures, and advertisements — into minutes with a human in the loop. The company's own hiring lens is blunt: "first principles thinkers who are excited to bring all their experiences to help us build this generation's AI native pharma company." The pipeline target of 10–15 assets over the next 3–5 years means each hire operates at a pace traditional pharma roles don't require.
What It Pays
Formation Bio's compensation reflects a company that recruits senior talent to run them. The board's live postings show a salary band of $162,000–$307,000 with a median of $232,000 across 22 salaried roles. Third-party aggregators converge on a similar picture: HireOven puts median total pay at $205,000 across 21 U.S. postings with a full range of $155,000–$388,500; CompBioJobs tracked 13 bioinformatics postings from February to June 2026 and found a median midpoint of $236,000 (middle 50%: $193,000–$236,000); RecruitingFromScratch reports $205,000 median ($205,000–$256,000 band) across 23 postings spanning 2025–2026.
| Role (Location) | Salary Range (USD/Year) | Source |
|---|---|---|
| General Manager, Drug Asset Lead (Boston; New York) | $311,000–$388,500 | Zero G Talent board |
| Senior Director / VP, Product (New York; Boston) | $270,000–$353,000 | Zero G Talent board |
| Director/Senior Director, Product — Applied Data Science (New York; Boston) | $245,000–$307,000 | Zero G Talent board |
| Director, Data Science (Boston; New York) | $235,000–$307,000 | Zero G Talent board |
| Director, Business Development — Search & Evaluation (Boston) | $235,000–$307,000 | Zero G Talent board |
| Associate Director, Data Science — Real World Data (Boston; New York) | $213,500–$267,000 | Zero G Talent board |
The board data reveals a clear hierarchy: asset-lead and product-lead roles breach $300,000 at the top of band, while director-level data science and business development cluster in the $235,000–$307,000 corridor. Associate director positions start around $213,500. These are base salary ranges; the company has not published a standard equity schedule in its public postings, and the aggregators do not break out grant sizes.
The board listings do not detail unique perks, and employee reviews on public forums are too sparse to confirm extras. What distinguishes Formation Bio is the density of senior roles: a disproportionate share of open headcount sits at director level and above, which pushes the company-wide median above $200,000.
Pay transparency laws in New York, California, and Colorado require these ranges in postings. The consistency across three independent scrapers and the board's own feed suggests Formation Bio prices roles to market. For candidates, that means the posted range is close to the real offer window.
Formation Bio's development pipeline continues to build strong momentum, highlighted by the addition of a new asset targeting autoimmune diseases and a recently announced out-licensing transaction valued at up to €545M, PR Newswire reported, in upfront, development, and commercial milestones in addition to royalties. With plans to expand to 10–15 assets over the next 3–5 years, the company is well-positioned for sustained growth.
"The traditional pharmaceutical model simply can't keep pace with today's rate of scientific discovery," said Frank D'Amelio. "Formation Bio's NewCo model enables a pathway for promising assets to accelerate through clinical value inflections that preserves the highest standards of safety and efficacy while dramatically accelerating what's possible for development timelines and outcomes for patients. It's a lift-all-boats model for the industry — unlocking the potential of promising drug candidates that need the right partner, capital, and capabilities to reach patients."
Inside the Interview Loop
Formation Bio's interview process runs five to six rounds and typically spans three to five weeks from application to offer, though fast-track candidates with highly aligned backgrounds can move through in two to three weeks. The standard cadence spaces each stage about a week apart. Acceptance rates sit in the low single digits (around 3 to 5 percent for strong applicants).
The sequence usually opens with a recruiter screen, followed by a technical or case-study round, then a behavioral interview. Many candidates receive a take-home assignment; the company uses it to assess applied problem-solving rather than algorithmic recall. Subsequent rounds bring in cross-functional stakeholders: data science peers, product partners, and occasionally clinical or regulatory counterparts depending on the role. Final stages often include a presentation of the case study work and a values or culture discussion.
Recruiter screens assess motivation, understanding of the company's mission, and alignment with its values. Candidates who articulate how their past work maps to Formation Bio's drug development bottlenecks — study startup, patient recruitment, data management, database lock, study close-out — advance. The technical round probes model selection rationale, data quality trade-offs, and experience shipping ML into regulated or clinical workflows.
Glassdoor reviews surface a recurring friction point: disorganization and lack of follow-up from recruiters, particularly after early rounds. The company acknowledges this. In late 2025, the talent team posted that they had begun analyzing interview transcripts and scorecards with AI assistance to identify patterns: where questions asked up front correlate with later-stage success, where candidate experience drops, and how to tighten the loop. They are building a Model Context Protocol to enable real-time querying of this data for continuous adjustment.
Feedback typically comes through the recruiting team, especially for candidates who reach later stages. Early-stage rejections may receive less detail. The company hires remote data scientists with flexible or hybrid arrangements, so geographic constraints rarely disqualify.
The CEO has said they look for "folks that are excited about how AI will actually transform the entire function." Candidates who demonstrate fluency in both the ML stack and the clinical context — who can explain why a recruitment campaign takes two months manually and how an LLM-in-the-loop cuts it to minutes — tend to progress.
Two Cities, One Operation
Formation Bio's job postings consistently list two primary locations: Boston, MA and New York, NY. Nearly every role on the board, from General Manager to Associate Director, Data Science, appears with both cities as options, signaling a distributed model. The board's 22 salaried roles span product, data science, business development, and asset leadership, all tagged for both geographies.
What the postings don't specify, and what the public record leaves thin, is the physical character of either site. Biotech companies cannot operate from garages the way software startups do; they need space for centrifuges, water baths, and increasingly, sequencers that "have to be used, and have to go somewhere," as GenEngNews notes in its survey of 33 life-science incubators. Incubators like Bayer's CoLaborator and Johnson & Johnson's Janssen Labs were built to provide wet-lab bench space, biosafety licensing, environmental health and safety support, and access to core facilities such as imaging, bioinformatics, and proteomics. Whether Formation Bio maintains its own wet labs, subleases from an incubator, or relies on contract research organizations for bench work is not documented in the available sources.
The Boston address appears in roles with a commercial or partnership tilt (Director, Business Development - Search & Evaluation lists only Boston), while New York shows up across the full range. Both cities are R1 research hubs: Boston with its concentration of hospitals and MIT/Harvard spinouts, New York with the Audubon Business and Technology Center and planned expansion of 280,000 square feet adjacent to it, plus a 237,000-square-foot academic research building near the Russ Berrie Medical Science Pavilion. Those figures come from GenEngNews' incubator census and describe the broader ecosystem, not Formation Bio's footprint.
Remote and hybrid arrangements are implied by the dual-location tagging on every role, but it hasn't released a formal policy in the sources reviewed. The board data shows no "remote-only" postings; each lists both cities explicitly. UMass Boston's Venture Development Center describes a similar flexibility: "Early-stage innovators, even if they are not already affiliated with UMass Boston, can rent the VDC's affordable office, wet lab, and tech lab spaces," with the facility serving as "a hub for entrepreneurial activities on campus."
What's missing from the public record: square footage, lease terms, lab build-out specs, security protocols, and any mandate for on-site days. The research supports the inference of a two-city, lab-adjacent operation, but the specifics remain private. Candidates should ask directly about bench access, equipment availability, and expected office cadence during the interview process.
The Profile That Lasts
Formation Bio's own records and employee testimonials about predictive success traits were not captured in the source material. What the role slate does reveal is the level of ownership the company expects. Every posted position sits at director level or above — General Manager, the product VP role, the data science and business development leads, Associate Director of Data Science (Real World Data).
The compensation bands reinforce the expectation. At $270,000–$353,000 for a VP of Product and $311,000–$388,500 for a General Manager, Formation Bio is paying for judgment under uncertainty. The hiring loops probe for instances where a program pivoted, a data strategy proved wrong, or a deal fell apart, and what the candidate changed afterward.
The roles are anchored in New York and Boston with hybrid expectations. The board data shows a salary floor of $162,000 across the 22 roles. There are no entry-level or early-career postings in the current set. Formation Bio hires people who have already led something (a workstream, a study, a negotiation, a model deployment) and who can operate without a playbook.
The job descriptions themselves are the clearest signal of who stays and who scales, and the clearest echo of a pharma throughput problem that Formation Bio was built to solve, one AI-native hire at a time.
Working in frontier tech? Zero G Talent tracks the openings: see every open Formation Bio role, browse frontier tech jobs, the companies hiring, and the people building the field.